Literature DB >> 123540

Visual hallucinations and delirium during treatment with amantadine (Symmetrel).

J U Postma, W Van Tilburg.   

Abstract

In 13 elderly patients, 12 of whom had Parkinson's disease, visual hallucinations and delirium developed as a side effect of amantadine hydrochloride (Symmetrel) therapy. The symptoms promptly disappearred when amantadine was discontinued. Thereafter, each parkinsonian patient was treated satisfactorily with levo-dopa. Treatment with a combination of amantadine and an anticholinergic agent increases the likelihood of delirium because of the hazard of retention of urine. Although amantadine is effective in the treatment of Parkinson's disease in the elderly, the incidence of delirium as a complication seems higher in this age group.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 123540     DOI: 10.1111/j.1532-5415.1975.tb00187.x

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  18 in total

1.  Visual hallucinations and agitation in Alzheimer's disease due to memantine: report of three cases.

Authors:  Roberto Monastero; Cecilia Camarda; Carmela Pipia; Rosolino Camarda
Journal:  J Neurol Neurosurg Psychiatry       Date:  2006-10-09       Impact factor: 10.154

Review 2.  Safety and Tolerability of Pharmacotherapies for Parkinson's Disease in Geriatric Patients.

Authors:  Martin Klietz; Stephan Greten; Florian Wegner; Günter U Höglinger
Journal:  Drugs Aging       Date:  2019-06       Impact factor: 3.923

Review 3.  [Parkinson's disease and psychoses].

Authors:  Jacopo Vittoriano Bizzarri; Giancarlo Giupponi; Ignazio Maniscalco; Patrizia Schroffenegger; Andreas Conca; Hans Peter Kapfhammer
Journal:  Neuropsychiatr       Date:  2015-01-14

4.  Toxic effects of amantadine in patients with renal failure.

Authors:  T S Ing; J T Daugirdas; L S Soung; H L Klawans; S D Mahurkar; J A Hayashi; W P Geis; J E Hano
Journal:  Can Med Assoc J       Date:  1979-03-17       Impact factor: 8.262

Review 5.  Neuropsychiatric adverse effects of antiparkinsonian drugs. Characteristics, evaluation and treatment.

Authors:  B K Young; R Camicioli; L Ganzini
Journal:  Drugs Aging       Date:  1997-05       Impact factor: 3.923

Review 6.  Pathophysiology and treatment of psychosis in Parkinson's disease: a review.

Authors:  Laura B Zahodne; Hubert H Fernandez
Journal:  Drugs Aging       Date:  2008       Impact factor: 3.923

Review 7.  Current Understanding of Psychosis in Parkinson's Disease.

Authors:  Oluwadamilola O Ojo; Hubert H Fernandez
Journal:  Curr Psychiatry Rep       Date:  2016-10       Impact factor: 5.285

Review 8.  Drug-induced psychiatric disorders and their management.

Authors:  L E Hollister
Journal:  Med Toxicol       Date:  1986 Nov-Dec

Review 9.  Clinical pharmacokinetics of amantadine hydrochloride.

Authors:  F Y Aoki; D S Sitar
Journal:  Clin Pharmacokinet       Date:  1988-01       Impact factor: 6.447

10.  Amantadine for adynamic speech: possible benefit for aphasia?

Authors:  Anna M Barrett; Paul J Eslinger
Journal:  Am J Phys Med Rehabil       Date:  2007-08       Impact factor: 2.159

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.